Location History:
- Readville, MA (US) (1991)
- Boston, MA (US) (1989 - 1994)
- Sharon, MA (US) (1997 - 2012)
Company Filing History:
11 out of 15 
3 out of 100 
2 out of 3 Years Active: 1989-2012
Title: Steven A. Bogen: Innovator in Blood Cell Separation Technology
Introduction
Steven A. Bogen, a prominent inventor based in Sharon, MA, has made significant contributions to the field of biotechnology, particularly in methods related to blood cell separation. With an impressive portfolio of 19 patents, he has focused on innovative techniques that facilitate the isolation of rare cell subpopulations from blood samples.
Latest Patents
Among his latest patents is a groundbreaking method for enriching rare cell subpopulations from blood. This innovative approach utilizes an antigen-dependent negative selection process, enabling the separation of rare circulating epithelial cells from blood by depleting erythrocytes. The technique involves the agglutination of erythrocytes using specific antibodies, such as anti-glycophorin A or glycophorin B, which target components present on erythrocytes, ensuring that the desired epithelial cells remain untrapped in the agglutinate.
Another notable patent encompasses a fluid exchange system for a sample chamber formed by a housing sealed against a microscope slide. This invention features fluid ports, including one above a well, that facilitates efficient rinsing and filling operations. In this design, rinse solutions are drawn from a reservoir to waste, while reagents are introduced into the chamber through a vacuum-driven mechanism, enhancing the process of sample preparation.
Career Highlights
Steven A. Bogen's career includes impactful tenures at Cytologix Corporation and Dako Denmark A/S, where he contributed his expertise in blood cell technologies. His work in these organizations has advanced the application of innovative separation methods in clinical and research settings.
Collaborations
Throughout his professional journey, Steven has collaborated with distinguished colleagues, including Herbert H. Loeffler and John A. Purbrick. These partnerships have fostered an environment of innovation, leading to the development of pioneering techniques that have benefited the scientific community.
Conclusion
With a robust portfolio of patents and a commitment to advancing cell separation technologies, Steven A. Bogen exemplifies the spirit of innovation in biotechnology. His contributions not only enhance research capabilities but also hold potential for significant advancements in medical diagnostics and treatment methodologies.